CytoDyn (STU:296) General and Admin. Expense: €6.06 Mil (TTM As of Feb. 2026)

CytoDyn STU:296 +3.13% 28 General and Admin. Expense is €6.06 Mil as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. CytoDyn's General and Admin. Expense for the three months ended in Feb. 2026 was €1.40 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2026 was €6.06 Mil.

CytoDyn General and Admin. Expense Related Terms

CytoDyn General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for CytoDyn's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn General and Admin. Expense Chart

CytoDyn Annual Data

Trend

May16

May17

May18

May19

May20

May21

May22

May23

May24

May25

General and Admin. Expense

Get a 7-Day Free Trial

28.25

41.91

15.77

10.01

6.44

CytoDyn Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Aug25	Nov25	Feb26
General and Admin. Expense	Get a 7-Day Free Trial															1.46	1.63	1.47	1.56	1.40

28GF Score

CytoDyn Inc STU:296

General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CytoDyn General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.06 Mil.

Frequently Asked Questions Learn more about General and Admin. Expense →

What does a General and Admin. Expense of €6.06 Mil mean?

CytoDyn (STU:296) has a General and Admin. Expense of €6.06 Mil as of Feb. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on CytoDyn and its competitors.

Is CytoDyn's General and Admin. Expense too high?

CytoDyn's current General and Admin. Expense is €6.06 Mil. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does CytoDyn's General and Admin. Expense compare to VSTM and IRD?

CytoDyn's General and Admin. Expense of €6.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good General and Admin. Expense for a Biotechnology company?

A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high General and Admin. Expense mean?

A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on CytoDyn and its competitors. CytoDyn's current General and Admin. Expense is €6.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CytoDyn stock overvalued right now?

CytoDyn (STU:296) has a current General and Admin. Expense of €6.06 Mil. The current General and Admin. Expense is €6.06 Mil. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is General and Admin. Expense calculated?

General and Admin. Expense is calculated from a company's financial statements. For CytoDyn (STU:296), the current General and Admin. Expense is €6.06 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Industry Healthcare Biotechnology

Comparable Companies VSTM IRD PALI PRLD GALT DMAC RCKT ABEO TENX LCTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CYDY:USA

Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website https://www.cytodyn.com

CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

28GF Score

Get the complete analysis for STU:296

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20

Price

View STU:296 Analysis

See General and Admin. Expense data for all stocks →